Evans et al. [49] analyzed 664 cases of stage I–III BC with a BRCA2 mutation in 5 databases and found consistent results that ER-positive tumor rates decreased as the age of onset decreased: < 40 years, 83%; 50–60 years, 79%; and ≥ 60 years, 76%. The gene discussed is BRCA2; the disease is breast cancer.